Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastr

What happened: Takeda said its Phase 3 G-HOPE-001 study of arcotatug tavatecan (TAK-921) met dual primary endpoints of overall survival and progression-free survival versus treatment of physician's choice in previously treated CLDN18.2-positive advanced gastric cancer. Key numbers: Median OS 10.2 vs Why it matters: Takeda said the findings support a planned regulatory filing in Japan and continued global development of arcotatug tavatecan in CLDN18.2-positive cancers, and a study author said the results highlight its potential as a new treatment option for patients with limited options.

Takeda said its Phase 3 G-HOPE-001 study of arcotatug tavatecan (TAK-921) met dual primary endpoints of overall survival and progression-free survival versus treatment of physician's choice in previously treated CLDN18.2-positive advanced gastric cancer.

Takeda said the findings support a planned regulatory filing in Japan and continued global development of arcotatug tavatecan in CLDN18.2-positive cancers, and a study author said the results highlight its potential as a new treatment option for patients with limited options.